DXCM
DEXCOM INC
NASDAQ · Healthcare · Medical - Devices · US
$88.48
+6.64%Year over year
Reported trailing growth
- Revenue
- +13.0%
- EBITDA
- +26.9%
- EBIT
- +57.4%
- EPS
- +40.0%
- Free cash flow
- +3.4%
- Operating cash flow
- -2.3%
Forward estimates
Based on analyst estimates
- Revenue
- +10.0%
- EBITDA
- +11.8%
- EPS
- +13.7%
Three-year CAGR
- Revenue
- +17.0%
- EBITDA
- +33.9%
- EBIT
- +32.6%
- Net income
- +34.8%
- EPS
- +34.5%
- Free cash flow
- +52.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026